**METABOLISM OF THE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR DELAVIRDINE IN MICE**

MAYLAND CHANG, VIRENDRA K. SOOD, GRACELLA J. WILSON, DAVID A. KLOOSTERMAN, PHILLIP E. SANDERS, MICHAEL J. HAUER, WEIRONG ZHANG, AND DANIEL G. BRANSTETTER

Drug Metabolism Research (M.C., V.K.S., G.J.W., P.E.S., M.J.H.); Structural, Analytical and Medicinal Chemistry (D.A.K.); and Investigative Toxicology (W.Z., D.G.B.), Pharmacia & Upjohn, Inc.

(Received December 2, 1996; accepted March 17, 1997)

ABSTRACT:
Delavirdine mesylate (U-90152T) is a highly specific nonnucleoside HIV-1 reverse transcriptase inhibitor currently under development for the treatment of AIDS. The excretion, disposition, brain penetration, and metabolism of delavirdine were investigated in CD-1 mice after oral administration of [14C]delavirdine mesylate at single doses of 10 and/or 250 mg/kg and multiple doses of 200 mg/kg/day. Studies were conducted with [14C]-carboxamide and [2-14C]-pyridine labels, as well as [13C3]-labeled drug to facilitate metabolite identification. Excretion was dose dependent with 57–70% of the radioactivity eliminated in feces and 25–36% in urine. Pharmacokinetic analyses of delavirdine and its N-desisopropyl metabolite (desalkyl delavirdine) in plasma showed that delavirdine was absorbed and metabolized rapidly, that it constituted a minor component in circulation, that its pharmacokinetics were nonlinear, and that its metabolism to desalkyl delavirdine was capacity limited or inhibitable. Delavirdine did not significantly cross the blood-brain barrier; however, its N-isopropylpyridinepiperazine metabolite—arising from amide bond cleavage—was present in brain at levels 2- to 3-fold higher than in plasma. The metabolism of delavirdine in the mouse was extensive and involved amide bond cleavage, N-desalkylation, hydroxylation at the C-6' position of the pyridine ring, and pyridine ring-cleavage as determined by MS and/or 1H and 13C NMR spectroscopies. N-desalkylation and amide bond cleavage were the primary metabolic pathways at low drug doses and, as the biotransformation of delavirdine to desalkyl delavirdine reached saturation or inhibition, amide bond cleavage became the predominant pathway at higher doses and after multiple doses.

Human immunodeficiency virus type 1 (HIV-1) infection resulting in AIDS is currently the leading cause of death in males 25 to 45 years of age in the United States (1). An important step in the replication of HIV-1 involves transcription of viral genomic RNA into proviral DNA by reverse transcriptase (2–4). Reverse transcriptase inhibitors such as 3'-azido-3'-oxythymidine (AZT, zidovudine) (5, 6), 2',3'-dideoxynosine (ddI, didanosine) (7–9), 2',3'-dideoxythymidine (ddT, stavudine) (10), and (-)-2',3'-didehydro-3'-deoxythymidine (d4T, stavudine) (11), (12) are nucleoside prodrugs that are converted by cellular enzymes to the active deoxynucleotide triphosphates that lack a free 3'-hydroxyl group and lead to chain termination and inhibition of viral replication. However, the serious toxic side effects (14) resulting from inhibition of cellular DNA polymerases (6, 8, 14, 15) and the emergence of resistant strains of the virus (16–20) have focused efforts on the development of specific nonnucleoside reverse transcriptase inhibitors. A new potent and highly specific HIV-1 reverse transcriptase inhibitor, delavirdine mesylate (U-90152T, fig. 1), was discovered recently (21, 22). Delavirdine selectively inhibited recombinant HIV-1 reverse transcriptase with an IC50 of 0.26 μM (22) and blocked viral replication in peripheral blood lymphocytes of 25 primary HIV-1 isolates, including strains which were highly resistant to AZT or ddI, with a 50% effective concentration of 0.066 μM (22). The potent inhibition of replication by delavirdine was comparable to the antiviral activity of nucleoside or other nonnucleoside reverse transcriptase inhibitors (21, 22). Delavirdine exhibited no significant inhibition of cellular polymerases α and β with IC50s of >440 μM (22). Delavirdine mesylate is currently under phase III clinical evaluations for the treatment of AIDS. This study describes the excretion, disposition, and brain penetration of delavirdine and its metabolites, and the isolation and identification of the metabolites of delavirdine after oral administration of [14C]delavirdine mesylate to male and female CD-1 mice after oral administration of [14C]delavirdine mesylate at single doses of 10 and/or 250 mg/kg and multiple doses of 200 mg/kg/day. Studies were conducted with [14C]-carboxamide and [2-14C]-pyridine labels, as well as [13C3]-labeled drug to facilitate metabolite identification. Excretion was dose dependent with 57–70% of the radioactivity eliminated in feces and 25–36% in urine. Pharmacokinetic analyses of delavirdine and its N-desisopropyl metabolite (desalkyl delavirdine) in plasma showed that delavirdine was absorbed and metabolized rapidly, that it constituted a minor component in circulation, that its pharmacokinetics were nonlinear, and that its metabolism to desalkyl delavirdine was capacity limited or inhibitable. Delavirdine did not significantly cross the blood-brain barrier; however, its N-isopropylpyridinepiperazine metabolite—arising from amide bond cleavage—was present in brain at levels 2- to 3-fold higher than in plasma. The metabolism of delavirdine in the mouse was extensive and involved amide bond cleavage, N-desalkylation, hydroxylation at the C-6' position of the pyridine ring, and pyridine ring-cleavage as determined by MS and/or 1H and 13C NMR spectroscopies. N-desalkylation and amide bond cleavage were the primary metabolic pathways at low drug doses and, as the biotransformation of delavirdine to desalkyl delavirdine reached saturation or inhibition, amide bond cleavage became the predominant pathway at higher doses and after multiple doses.

![Fig. 1. Structure of delavirdine mesylate including the positions of the 14C and 13C labels.](image-url)

---

*Abbreviations used are: HIV-1, human immunodeficiency virus type 1; IC50, median inhibitory concentration; LSC, liquid scintillation counting; DMSO, dimethylsulfoxide; PB, particle beam; CI, chemical ionization; LC, liquid chromatography; MS, mass spectrometry; PCI, positive chemical ionization; EI, electron ionization; 2D, two-dimensional; DEPT, distortionless enhancement by polarization transfer; COSY, correlation spectroscopy; HMQC, heteronuclear multiple-quantum correlation; GARP, globally optimized alternating-phase rectangular pulses; HMBC, heteronuclear multiple-bond correlation.*

Send reprint requests to: Dr. Mayland Chang, Drug Metabolism Research, Pharmacia & Upjohn, Inc., Kalamazoo, MI 49007.

---
mice. Studies were conducted with $^{14}$C-carboxamide and 2-14C-pyridine labels, as well as $^{13}$C$_3$-labeled drug to facilitate metabolite identification.

Materials and Methods

Chemicals. All chemicals used in this study were of analytical grade. Solvents were Burdick & Jackson high purity grade (Burdick & Jackson, Muskegon, MI), Water was distilled and purified through a Milli-Q reagent water system (Millipore Corp., Bedford, MA), Ultima Gold (Packard Instruments, Meriden, CT) was used for liquid scintillation counting (LSC). Carbosorb E (Packard) and Permafluor E$^{+}$ (Packard) were used for combustion of samples. Ultima-Flo M (Packard) was used as scintillant for flow-through detection. β-Glucuronidase (Helix pomatia, Type H-5) was obtained from Sigma Chemical Company (St. Louis, MO). Methanol-d$_4$ (99.96% D) and DMSO-d$_6$ were purchased from Cambridge Isotope Laboratories (Cambridge, MA).

Delavirdine mesylate, [1$^{14}$C-carboxamide]delavirdine mesylate, [1$^{13}$C$_3$]delavirdine mesylate, [2-14C-pyridine]delavirdine mesylate, U-96183, U-102466, U-88703, U-88822, U-96364, and U-91976 were synthesized by M. Phillips in the Chemistry Department at Packard. Delavirdine mesylate and [14C-carboxamide]delavirdine mesylate were synthesized by F. Iacovelli and C. M. Leck in the Radiomet Development Laboratory at Packard. Delavirdine methanesulfonate were dissolved in 80% propylene glycol/20% water containing 3 µM $^{13}$C$_3$-glucuronic acid.

CD-1 mice were obtained from Charles River Laboratories (Portage, MI). Male mice weighed 23–37 g and were 6–7 weeks old at dosing. Female mice weighed 17–29 g and were 7–8 weeks old. For excretion studies, mice were placed in individual Nalgene metabolism cages equipped with urine and feces separators. Mice were used for collection of blood samples and in the brain penetration study were housed in stainless steel cages with wire mesh floors. Environmental conditions were maintained as follows: lights 12 hr on/12 hr off, relative humidity 41–64%, temperature 68–75°F, ventilation 18–20 room air changes per hr. Mice were provided with a pelleted diet (PMI Feeds Inc., St Louis, MO) and water ad libitum. Mice were fasted approximately 3 hr before and 1 hr after radiolabeled dose administration. The animals in this study were cared for and used in accordance with The Guide for the Care and Use of Laboratory Animals, DHEW (National Institutes of Health) 85–23, 1985 and with The Animal Welfare Act Regulation 9 CFR 3, August 15, 1989 and as modified on March 19, 1991.

Instrumentation. Samples were oxidized in a Packard Model 307 sample oxidizer (Packard Instrument Co., Meriden, CT) equipped with a Packard Oximate 80 robotics system. A Packard Tri-Carb Liquid Scintillation Analyzer Model 1900 CA or Model 1900TR was used for radioactivity counting. Feces were homogenized using a Stomacher Blender (Tekmar Co., Cincinnati, OH). A TurboVap LV evaporator (Zymark Corporation, Hopkinton, MA) or a Radiomatic Model A-515 or A-525 flow-through detector (Packard Instrument Company, Billerica, MA) was used to concentrate samples. A Packard Tri-Carb Liquid Scintillation Analyzer Instrumentation (Packard) and Permafluor E$^{+}$ (Packard) were used for combustion of samples. Ultima-Flo M (Packard) was used as scintillant for flow-through detection. β-Glucuronidase (Helix pomatia, Type H-5) was obtained from Sigma Chemical Company (St. Louis, MO). Methanol-d$_4$ (99.96% D) and DMSO-d$_6$ were purchased from Cambridge Isotope Laboratories (Cambridge, MA).

Electrospray ionization-mass spectrometry (ESI-MS) was performed on a Finnigan-MAT TSQ 7000 triple quadrupole mass spectrometer (Finnigan-MAT, San Jose, CA) directly coupled to the HPLC system via a Finnigan atmospheric pressure ionization (API) source operated in the ESI mode. The HPLC system consisted of a Hewlett Packard 1050 Series pump and autosampler (Hewlett Packard, Naperville, IL), and a Thar two position valve actuator (Thar Designs Inc., Pittsburgh, PA). The mobile phase was the same as for PB-LC-MS, except for a flow rate of 1.0 ml/min. Flow to the mass spectrometer was split 1:2.

Nuclear Magnetic Resonance Spectroscopy. $^1$H NMR spectra were recorded at 500 MHz using a Bruker AMX-500 spectrometer (Bruker Instruments Inc., Billerica, MA). Data were processed on a Bruker X-32 computer using Bruker UXNMR software version 930901.3. Samples were dissolved in approximately 300–500 μl methanol-d$_4$ in a 3 mm i.d. Teflon insert (WIL-MAD, Buena, NJ); the Teflon insert was placed in a 5 mm NMR tube (WIL-MAD). Spectra were recorded at a temperature of 300 K as free induction decays of 32K complex points. The residual CHD$_2$OH pentet was used as reference at 3.30 ppm.

UV spectra were recorded in the magnitude mode using 1K by 1K data table with 256 increments in F1 and no zero-filling in F2. Unshifted sinebell windows were applied before transformation.

2D $^1$H COSY spectra were recorded in the magnitude mode using 1K by 1K data table with 256 increments in F1 and no zero-filling in F2. Unshifted sinebell windows were applied before transformation.

2D inverse $^1$H–$^1$C HMBC spectra (23) were recorded in the magnitude mode with a relaxation delay of 0.8 sec. GARP decoupling of $^1$C during acquisition (24), a 1K by 512W data table, and 128 increments in F1 with no zero-filling in F2. Sinebell-squared window functions shifted n/2 radians were applied in both F2 and F1.

2D inverse $^1$H–$^1$C HMBC spectra (25) were recorded using the same conditions described for the HMQC spectra except that a relaxation delay of 1.0 sec was used with no $^1$C decoupling. The low-pass J-filter was optimized for 6 Hz to suppress crosspeaks arising from $^{1}$H–$^{1}$C-one-bond correlations.

$^{13}$C NMR spectra were recorded at 125.75 MHz using a Bruker AMX-500 spectrometer. One-dimensional $^{13}$C and $^{13}$C–$^1$H DEPT (26) spectra were recorded as free induction decays of 32K complex points, using a 30$^\circ$ $^1$C pulse and a repetition rate of approximately 1 sec with proton decoupling. The free induction decay was zero-filled once, multiplied by a slightly line-broadening (LB = 1 Hz) decaying exponential function, and Fourier transformed. Methanol-d$_4$ was used as reference at 49.0 ppm.

Ultraviolet Spectrometry. UV spectra were obtained on a Perkin Elmer LC-235C diode array detector as described previously (27).

Dosing and Sample Collection. Doses were measured gravimetrically and administered by oral gavage using a dosing syringe attached to an animal feeding needle. Blood samples were stored on ice and centrifuged to separate the plasma. Urine, feces, and tissue samples were collected at room temperature, immediately analyzed, or stored at $-20^\circ$ C until further analysis.

Single-Dose Excretion and Metabolism [$^{14}$C-Carboxamide]Delavirdine Mesylate Study. Delavirdine mesylate and [1$^{14}$C-carboxamide]delavirdine mesylate were dissolved in 80% propylene glycol/20% water containing 3 µM methanesulfonic acid per ml to final concentrations of 2 and 50 mg/ml. Thirty-one male and 31 female mice received single oral doses of approximately 10 mg/kg and 585 µC/kg, and 31 male and 31 female mice were administered single oral doses of approximately 250 mg/kg and 595 µC/kg. Urine was collected from 4 mice/sex/dose over 0–12, 12–24, and 24-hr intervals up to 120 hr post-dose; feces were collected over 0–24 and at 24-hr intervals up to 120 hr after dosing. Terminal blood samples were collected by cardiac puncture from the remaining mice (3 mice/sex/dose/time point) at scheduled times through the 48-hr period following the radiolabeled dose.

Multiple-Dose Excretion and Metabolism [$^{14}$C,1$^{13}$C-Carboxamide]-Delavirdine Mesylate Study. Equimolar amounts of delavirdine mesylate and [$^{14}$C,1$^{13}$C]-delavirdine mesylate were dissolved and 80% propylene glycol/20% water containing 3 µM methanesulfonic acid per ml to a final concentration of 20 mg/ml. Three male

Downloaded from dmd.aspetjournals.org at ASPECT Journals on June 15, 2017
mice received multiple oral radiolabeled doses of 200 mg/kg/day and 272 μCi/kg/day. Doses were given twice a day, one dose in the morning and a second dose 8 hr later for 4.5 days. Urine and feces were collected at 24-hr intervals up to 216 hr after the first dose. A terminal blood sample was collected from one mouse by cardiac puncture 4 hr after the last dose; urine and feces from this mouse were collected at 24-hr intervals up to 96 hr after the first dose.

**Single-Dose Excretion and Metabolism [2-14C-Pyridine]Delavirdine Mesylate Study.** Delavirdine mesylate and [2-14C-pyridine]delavirdine mesylate were dissolved in 80% propylene glycol/20% water containing 3 μl methanesulfonic acid per ml to a final concentration of 50 mg/ml. Six male mice were administered single oral doses of approximately 250 mg/kg and 1,200 μCl/kg. Terminal blood was collected from 3 mice at 0.5, 1, and 2 hr after dosing. Urine and feces were collected from the remaining 3 mice; urine over the time periods 0–12, 12–24, 24–48, and 48–72 hr after dosing, and feces at 24-hr intervals to 72 hr post-dose.

**Single-Dose Brain Penetration [2-14C-Pyridine]Delavirdine Mesylate Study.** Delavirdine mesylate and [2-14C-pyridine]delavirdine mesylate were dissolved in 50% propylene glycol/50% water containing 3 μl methanesulfonic acid per ml to a final concentration of 50 mg/ml. Twelve female mice were administered single oral doses of approximately 250 mg/kg and 975 μCl/kg. Terminal blood and excised unperfused tissues (brain and pituitary) were collected at 1, 4, 12, and 24 hr after dosing.

**Sample Preparation and Total Radiocarbon Analysis.** Aliquots of urine (3 replicates) and plasma (1–2 replicates) were analyzed by LSC. Whole blood (2 replicates), feces (3–5 replicates), and brain (3 replicates) were combusted prior to LSC analysis. Feces and brain were homogenized with 3–5 volumes of water with and without 2% acetic acid, respectively.

The combustion efficiency of the sample oxidizer was determined by comparing the radioactivity recovered from replicate oxidations of pre-dose feces, whole blood, or tissue fortified with a known amount of [14C-carboxamide] or [2-14C-pyridine]delavirdine mesylate to that obtained by direct fortification of the Carbo-sorb/Permafluor trapping solution with the same amount of [14C-delavirdine mesylate]. The efficiency was calculated at the start of a series of oxidations, as well as intermittently, to ensure that the oxidizer efficiency did not change substantially; concentrations were corrected for combustion efficiency. Radioactivity was measured by LSC with 2–20 min counting. Count rates in cpm were converted to dpm using quench curves generated from sealed quenched standards in either Ultima Gold or Carbo-sorb/Permafluor cocktails.

**HPLC Analyses of Plasma for Delavirdine and Desalkyl Delavirdine.** Plasma samples from the single-dose excretion and metabolism [14C-carboxamide]delavirdine mesylate study were analyzed for delavirdine and desalkyl delavirdine as follows: A 25-μl aliquot of plasma was mixed with 75 μl internal standard solution in acetonitrile (1 μg/ml U-88822 in acetonitrile) and centrifuged at 14,000 rpm for 5 min at 4°C. A 90-μl aliquot of the supernatant was evaporated to dryness and reconstituted in 200 μl of 10% acetonitrile/90% 0.1 M ammonium acetate buffer (pH 4), and a 100-μl portion was analyzed by HPLC with UV detection at 295 nm. The HPLC conditions consisted of isocratic elution on a YMC 5μ-basic 4.6 mm i.d. × 25 cm column at a flow of 1.0 ml/min with 34% acetonitrile/2% isopropyl alcohol/64% 0.1 M ammonium acetate buffer (pH 4). Quantitation of delavirdine and desalkyl delavirdine in plasma was determined using peak area ratios relative to the internal standard and linear regression parameters calculated from calibration curve standards. Calibration curve and quality control standards were prepared similarly in blank mouse plasma.

**Pharmacokinetic Analysis.** Pharmacokinetic parameter estimates were determined by noncompartmental analyses of the dose-normalized mean concentration-time data for drug-related material, delavirdine, and desalkyl delavirdine. AUC was determined by the linear trapezoidal rule. Half-lives were estimated from the terminal linear portion of the dose-normalized mean concentration-time data by linear regression, where the slope of the line was the rate constant k and \( t_{1/2} = \ln 2/k \). \( t_{max} \) was the time at which maximum concentration (C \( max \)) was achieved; both values were based on the highest observed concentrations.

**HPLC Profiles of Plasma, Urine, Feces, and Brain Samples.** Plasma, urine, feces, and brain samples were analyzed for delavirdine and desalkyl delavirdine. The analysis involved fortification with internal standards and subsequent extraction and cleanup. The samples were then analyzed by HPLC with UV detection at 295 nm. The chromatograms showed clear peaks for delavirdine and desalkyl delavirdine, allowing for quantification and comparison of concentrations across different samples.
were extracted with acetone (96% 6). Radioactivity from the sum of the integrated peaks in the 14C chromatogram area integration. Column recovery was determined by comparing the total peaks of radioactivity were quantified on the Radiomatic detector using peak buffer (pH 4)). The HPLC effluent was mixed with Ultima-Flo M in a 1:3 ratio. A/40% D for 5 min (where A for 5 min, followed by a 35-min linear gradient to 60% A/40% D, then 60% i.d.

metabolism [13 C 3 ,14 C-carboxamide]delavirdine mesylate (recoveries of approximately 98% for feces and 101.5% for brain). Chromatographic analyses were performed on a YMC 5μ-basic 4.6 mm i.d. × 25 cm column using gradient elution at 1.0 ml/min with 10% A/90% D for 5 min, followed by a 35-min linear gradient to 60% A/40% D, then 60% A/40% D for 5 min (where A = acetonitrile, D = 0.1 M ammonium acetate buffer (pH 4)). The HPLC effluent was mixed with Ultima-Flo M in a 1:3 ratio. Peaks of radioactivity were quantified on the Radiomatic detector using peak area integration. Column recovery was determined by comparing the total radioactivity from the sum of the integrated peaks in the 14C chromatogram with total radioactivity; essentially all of the injected radioactivity was recovered from the column.

Metabolite Isolation. MET-10 was isolated as follows: Urine (48 ml, 12.66 × 10^6 dpm, 4.2 mg of drug-related material) collected over the time period 0–24 hr from three mice in the multiple-dose excretion and metabolism [13 C 3 ,14 C-carboxamide]delavirdine mesylate study was lyophilized. The residue was dissolved in 4.8 ml 10% acetonitrile/90% 0.1 M ammonium acetate (pH 4) to afford 12.3 × 10^6 dpm, 4.1 mg of drug-related material. A portion of the concentrated urine (10.5 × 10^6 dpm, 3.5 mg drug-related material) was purified by HPLC with gradient elution (YMC 5μ-basic 4.6 mm i.d. × 25 cm, 21 injections of 200 μl each, 1.0 ml/min, 5-min 10% A/90% D, 35-min linear gradient to 60% A/40% D, 5-min 60% A/40% D, where A = acetonitrile, D = 0.1 M ammonium acetate buffer (pH 4)) to give 1.2 mg (3.6 × 10^6 dpm) of partially purified MET-10. A final HPLC purification with isocratic elution (Zorbax 5μ-SB-CN 4.6 mm i.d. × 25 cm, 11 injections of 100 μl each, 1.0 ml/min, 10% acetonitrile/90% 0.1 M ammonium acetate buffer (pH 4) afforded 1.0 mg (3.0 × 10^6 dpm) of purified MET-10.

Metabolite Identification. Concentrated plasma (2 hr post-dose from four male mice given 250 mg/kg single doses of [13 C 3 ,14 C-carboxamide]delavirdine mesylate) and urine (48–72 hr from the multiple-dose excretion and metabolism [13 C 3 ,14 C-carboxamide]delavirdine mesylate and 0–12 hr from the single-dose excretion and metabolism [2-14 C-pyridine]delavirdine mesylate study) were analyzed by EI and PCI-PB-LC-MS. The purified MET-10 was dissolved in ~400 μl methanol-d 4 and analyzed by one-dimensional 1H NMR, 2D COSY NMR, 2D HMOC NMR, and 2D HMBC NMR. A 50-μl portion of MET-10 in methanol-d 4 was diluted with 50 μl water for EI-PB-MS analysis.

Enzyme Hydrolysis. Plasma (deproteinized and concentrated samples 0.5 hr post-dose from 3 male mice given 10 mg/kg single doses of [13 C 3 ,14 C-carboxamide]delavirdine mesylate and 1 hr post-dose from a male mouse in the single-dose excretion and metabolism [2-14 C-pyridine]delavirdine mesylate study) and urine (0–12 hr from one mouse in the single-dose excretion and metabolism [2-14 C-pyridine]delavirdine mesylate study) were mixed (1:1) with 0.1 M sodium acetate (pH 5) and 200 μl β-glucuronidase solution (500 units/ml in 0.2% saline), followed by incubation at 37°C for 1 hr. Samples were analyzed by HPLC with flow-through radiochemical detection using gradient elution (vide supra). Control plasma and urine samples were prepared in 0.1 M sodium acetate (pH 5) and 200 μl 0.2% saline, followed by incubation at 37°C for 1 hr.

Acid Hydrolysis. Plasma supernatant (from the 10 mg/kg single-dose excretion and metabolism [14 C-carboxamide]delavirdine mesylate and single-
Dose excretion and metabolism [2-14C-pyridine]delavirdine mesylate studies) and urine (0–12 hr from one male mouse in the single-dose excretion and metabolism [2-14C-pyridine]delavirdine mesylate study) were mixed (1:1) with 1 N HCl, followed by incubation at 88°C for 1 hr. After cooling, a 100-µl aliquot was analyzed by HPLC with flow-through radiochemical detection using gradient elution (vide supra). Control plasma and urine samples in 200 µl 10% acetonitrile/90% 0.1 M ammonium acetate (pH 4) were carried out similarly.

Results

Mass Balance. The cumulative excretion of drug-related radioactivity following single and multiple oral dose administration of [14C-carboxamide]delavirdine mesylate and after single oral dose administration of [2-14C-pyridine]delavirdine mesylate is shown in fig. 2. Mean recoveries were 57–70% in feces, 25–36% in urine, for total recoveries (including cagewash) of 94–96%. Most of the dose (>87%) was excreted within 24 hr after dosing.

Plasma Concentrations and Pharmacokinetics. Absorption was rapid as evidenced by mean t_{max} values for drug-related material, delavirdine, and desalkyl delavirdine, which ranged from 0.5 to 4.0 hr (fig. 3, table 1). Mean AUC of drug-related material and desalkyl delavirdine increased proportionately with dose; however, mean AUC of delavirdine increased more than proportionately with drug dose. Concentrations of desalkyl delavirdine were significantly higher than delavirdine concentrations.

Desalkyl delavirdine was the major (72.5–81.9%) radioactive component in circulation after single doses of both [14C-carboxamide]delavirdine mesylate and [2-14C-pyridine]delavirdine mesylate. Delavirdine was also observed in circulation, ranging from 0.9% to 18.2%. The remaining radioactivity in plasma was associated with MET-3 (6.1–17.7%), MET-6 (0.2–2.2%), and MET-10 (0.3–0.9%) or MET-12 (1.1%). Gender-related differences in metabolite profiles were not observed.

Distribution of Delavirdine and its Metabolites into Brain Tissue. Concentrations of drug-related material in brain and pituitary reached a maximum 1 hr after drug administration and were 7.2 ± 0.7% and 168 ± 18% of corresponding levels in plasma, respectively. HPLC analyses of plasma and brain showed that the N-isopropylpyrindinepiperazine metabolite constituted 1.1% and 72% of the radioactivity in plasma and brain, respectively. Brain concentrations of the N-isopropylpyrindinepiperazine metabolite were 2- to 3-fold higher than those observed in plasma. In contrast, delavirdine concentrations in brain were 2.7% of plasma 1 hr after drug administration.

HPLC Profiles of Urine and Feces. The metabolism of delavirdine was extensive in the mouse, with a small amount of the administered dose excreted as intact drug (<3% of the dose, table 2) following single or multiple doses of [14C-carboxamide]delavirdine mesylate. At low single doses of the [14C-carboxamide] labeled drug, the major components in urine were MET-5 and MET-10, with MET-5 present in slightly higher levels than MET-10. At high single doses and following multiple doses of [14C-carboxamide]delavirdine mesylate, MET-10 was the major component in urine, while MET-5 was present in lower amounts. With the [2-14C-pyridine] label, MET-12 was the major component in urine and MET-5 was present in lower levels. Several minor metabolites were also observed in urine; MET-9 was only observed following multiple doses. Feces contained mostly MET-2 after multiple doses of [14C-carboxamide]delavirdine mesylate, and mostly intact drug after a 250 mg/kg single-dose of [2-14C-pyridine]delavirdine mesylate. Representative chromatograms are shown in fig. 4.

MET-2, MET-5, MET-12, MET-13, and Delavirdine. The presence of despyridinyl delavirdine (MET-2), desalkyl delavirdine

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Excretion of delavirdine and its metabolites after single and multiple oral dose administration of [14C-carboxamide]delavirdine mesylate</strong></td>
</tr>
<tr>
<td><strong>Dose mg/kg/day</strong></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>250</td>
</tr>
<tr>
<td>200</td>
</tr>
<tr>
<td><strong>Mean ± SD in percent of administered dose values for feces were corrected for extraction recovery. Other minor metabolites are not listed. ND, not detected.</strong></td>
</tr>
</tbody>
</table>

Desalkyl delavirdine was the major (72.5–81.9%) radioactive component in circulation after single doses of both [14C-carboxamide]delavirdine mesylate and [2-14C-pyridine]delavirdine mesylate. Delavirdine was also observed in circulation, ranging from 0.9% to 18.2%. The remaining radioactivity in plasma was associated with MET-3 (6.1–17.7%), MET-6 (0.2–2.2%), and MET-10 (0.3–0.9%) or MET-12 (1.1%). Gender-related differences in metabolite profiles were not observed.

Distribution of Delavirdine and its Metabolites into Brain Tissue. Concentrations of drug-related material in brain and pituitary reached a maximum 1 hr after drug administration and were 7.2 ± 0.7% and 168 ± 18% of corresponding levels in plasma, respectively. HPLC analyses of plasma and brain showed that the N-isopropylpyrindinepiperazine metabolite constituted 1.1% and 72% of the radioactivity in plasma and brain, respectively. Brain concentrations of the N-isopropylpyrindinepiperazine metabolite were 2- to 3-fold higher than those observed in plasma. In contrast, delavirdine concentrations in brain were 2.7% of plasma 1 hr after drug administration.

HPLC Profiles of Urine and Feces. The metabolism of delavirdine was extensive in the mouse, with a small amount of the administered dose excreted as intact drug (<3% of the dose, table 2) following single or multiple doses of [14C-carboxamide]delavirdine mesylate. At low single doses of the [14C-carboxamide] labeled drug, the major components in urine were MET-5 and MET-10, with MET-5 present in slightly higher levels than MET-10. At high single doses and following multiple doses of [14C-carboxamide]delavirdine mesylate, MET-10 was the major component in urine, while MET-5 was present in lower amounts. With the [2-14C-pyridine] label, MET-12 was the major component in urine and MET-5 was present in lower levels. Several minor metabolites were also observed in urine; MET-9 was only observed following multiple doses. Feces contained mostly MET-2 after multiple doses of [14C-carboxamide]delavirdine mesylate, and mostly intact drug after a 250 mg/kg single-dose of [2-14C-pyridine]delavirdine mesylate. Representative chromatograms are shown in fig. 4.

MET-2, MET-5, MET-12, MET-13, and Delavirdine. The presence of despyridinyl delavirdine (MET-2), desalkyl delavirdine
(MET-5), the N- isopropylpyridinepiperazine metabolite (MET-12), N-desisopropylpyridinepiperazine (MET-13), and delavirdine in urine and/or plasma was indicated by HPLC retention time and UV spectrum comparisons to synthetic standards. Structures were confirmed by comparison of the mass spectra of the metabolites (table 3, fig. 5) with those of synthetic standards.

MET-3. This minor component in plasma and urine was tentatively characterized as a thermally-labile conjugate of desalkyl delavirdine based on time-course profiles and enzyme and acid hydrolyses.

MET-1 and MET-4a. These minor metabolites in urine and feces were characterized as a conjugate and the sulfate conjugate of despyridinyl delavirdine, respectively, based on retention time comparison to MET-1 from rat feces (27) and MET-4a from dog urine (28).

MET-14. MET-14 was observed as a minor radioactive peak in urine after administration of [2-14C-pyridine]delavirdine mesylate, but was not present after treatment with [14C-carboxamide]delavirdine mesylate (fig. 4) and suggested that the structure of MET-14 lacked the carboxamide carbon. MET-14 in mice was characterized as the pyridine ring-opened metabolite based on HPLC retention time comparison with MET-14 isolated from rat feces and identified by 1H NMR and MS-MS (27).

MET-6 and MET-7. These minor metabolites were observed in plasma and urine. Treatment of plasma and urine with β-glucuronidase (containing glucuronidase and sulfatase activities) or with acid resulted in the disappearance of MET-6 concomitant with an increase in MET-7. On further standing at room temperature, MET-7 degraded to despyridinyl delavirdine (MET-2) and to the pyridine ring-opened MET-14. These data suggested that MET-6 was a glucuronide or sulfate conjugate of MET-7.

Confirmation of MET-6 as a glucuronide was pursued by LC-MS analysis. However, because of the minor presence of this metabolite in mouse urine spectroscopic confirmation could not be obtained. MET-6 was characterized as 6′-O-glucuronide delavirdine based on HPLC retention time comparison with MET-6 isolated from rat bile and identified by 1H NMR and MS (27).

Confirmation of MET-7 as 6′-hydroxy delavirdine was obtained by LC-MS. Analysis of urine from a mouse given [13C3, 14C-carboxamide]delavirdine mesylate by CI-MS showed protonated molecular ions at m/z 473 and 476 (table 3), 16 amu higher than parent drug and indicative of the presence of a hydroxyl group. Cleavage of the pyridine-piperazine linkage gave ions at m/z 323 and 326, as well as an ion at m/z 153. The ion at m/z 153 was 16 amu higher than the corresponding ion for parent drug and established substitution on the pyridine ring. These data, together with the fact that enzyme hydro-
lysis of 6-O-glucuronide delavirdine (MET-6) generated MET-7, identified MET-7 as 6-hydroxy delavirdine. MET-10 was observed in mice treated with [14C-carboxamide]delavirdine mesylate, but not in mice given and [2-14C-pyridine]delavirdine mesylate. This metabolite eluted at the same HPLC retention time as the synthetic standard U-96364 (indole carboxylic acid metabolite). Confirmation of MET-10 was initially pursued by LC-MS. However, no spectroscopic information could be obtained because of the insensitivity of the technique for this metabolite. Therefore, MET-10 was isolated from mouse urine. MET-10 showed a UV λmax at 293 nm, characteristic of the presence of an indole ring. The 1H NMR spectrum (500 MHz, methanol-d4, fig. 6, table 4) showed the presence of four aromatic protons and a methylsulfonamido group. Resonances for the pyridine and piperazine rings, as well as those for the isopropyl side chain were not observed. All four aromatic protons were similar to corresponding resonances in the parent drug (fig. 6, table 4) and were assigned to protons on the indole ring. The resonances at 6.74 and 7.09 ppm corresponded to H-3 split into two doublets owing to 2JCH coupling of 7.5 Hz between C-2 and H-3 and 3JCH coupling of 175 Hz between C-3 and H-3. Therefore, the singlet at 6.91 ppm integrating for 0.6 protons corresponded to H-3 in the unenriched (99% 13C) metabolite and the two doublets at 6.74 and 7.09 ppm integrating for 0.2 protons each were assigned to H-3 in the 13C3-enriched metabolite. Thus, approximately 60% of MET-10 was unenriched and ~40% was 13C3-enriched. Assignments were confirmed with a 2D COSY experiment.

To confirm the assignments, a 13C NMR experiment (table 5) was carried out taking advantage of the fact that this metabolite was 13C3-enriched and, therefore, the small amount of isolated metabolite would not be a problem. Carbon assignments were determined with a 2D HMBC experiment in which the chemical shifts of the protons were correlated to the carbons by means of two-bond and three-bond C-H couplings. The 13C NMR assignments for MET-10 indicated the presence of ten carbons. These data together with the 1H NMR resonances suggested the presence of a carboxylic function in MET-10. Particle beam EI-MS confirmed this assignment, which showed isotopic molecular ions at m/z 254 and 257 (doublets 3 amu apart owing to the presence of 13C3) corresponding to the addition of a carboxylic acid to the methylsulfonamido indole ring (fig. 5, table 3). Cleavage of CH3 SO2 gave isotopic fragments at m/z 179 and 207, loss of H2O gave ions at m/z 157 and 160, with further loss of CO resulting in a fragment at m/z 130. These spectroscopic data identified MET-10 as the indole carboxylic acid metabolite (U-96364). The identity of MET-10 was further confirmed with a synthetic standard, which had identical HPLC retention time as well as a similar EI mass spectrum. However, the 1H and 13C NMR spectra of the synthetic standard were similar to the spectra of MET-10 with few exceptions, which could be explained by the metabolite being a carboxylate salt and the synthetic standard a free carboxylic acid. Assignments were confirmed by addition of triethylamine to the methanol-d4 solution of U-96364 which resulted in chemical shifts to 6.94 ppm for H-3, 136.2 ppm for C-2, 105.3 ppm for C-3, and 168.4 ppm for the carbonyl carbon.
Fig. 5. Mass spectra of delavirdine and its metabolites.

Top to bottom: EI mass spectrum of delavirdine from mouse plasma; CI mass spectrum of MET-5 from mouse urine; EI mass spectrum of MET-10 from mouse urine.
Salkyl delavirdine was the major drug-related material in circulation, dide to desalkyl delavirdine was capacity-limited or inhibitable. Decreasing dose and suggested that the biotransformation of delavirdine. AUC of desalkyl delavirdine to AUC of delavirdine decreased with increasing more than proportionately with dose. The ratio of delavirdine. The pharmacokinetics of delavirdine were nonlinear, with significantly higher concentrations of desalkyl delavirdine than intact delavirdine. The biotransformation of delavirdine and desalkyl delavirdine was dose dependent; at higher doses and after multiple doses the indole carboxylic acid or N-isopropylpyridine metabolites were present in higher levels than desalkyl delavirdine. These results were consistent with the biotransformation of delavirdine to desalkyl delavirdine reaching saturation or inhibition. In addition, despiridyl delavirdine (MET-2), the conjugate of the indole carboxylic acid metabolite (MET-9), the thermally labile (MET-3) and sulfate (MET-4a) conjugates of desalkyl delavirdine, 6’-hydroxy delavirdine (MET-7) and its glucuronide conjugate (MET-6), and the N-desisopropylpyridinepiperazine metabolite (MET-13, U-91976) were detected as minor components in mouse urine. In contrast, desalkyl delavirdine was the major (5–12% of the dose) drug-related material in rat urine, while MET-10 and MET-12 were very minor components (27). Radioactivity in mouse feces was mostly composed of despiridyl delavirdine or intact delavirdine after administration of [14C-carboxamide] or [2-14C-pyr-idine]delavirdine mesylate, respectively. The differences in metabolite profiles obtained with the carboxamide and pyridine14C labels and the HPLC analysis of pre-dose feces fortified with [14C-carboxamide]delavirdine mesylate suggested that bacterial metabolism of delavirdine may account for the presence despiridyl delavirdine and MET-14 via degradation of 6’-hydroxy delavirdine.

Delavirdine was metabolized by the mouse to several metabolites. Unchanged delavirdine was not detected in urine, indicating extensive metabolism. In urine, desalkyl delavirdine and the indole carboxylic acid or N-isopropylpyridinepiperazine metabolites were the major components. These metabolites accounted for 17–27% of the administered dose and were present in roughly equal amounts. At low drug doses, the amounts of desalkyl delavirdine were slightly higher than those of the indole carboxylic acid metabolite, while at high drug doses and after multiple doses the indole carboxylic acid or N-isopropylpyridinepiperazine metabolites were present in higher levels than desalkyl delavirdine. These results were consistent with the biotransformation of delavirdine to desalkyl delavirdine reaching saturation or inhibition. In addition, desspiridyl delavirdine (MET-2), the conjugate of the indole carboxylic acid metabolite (MET-9), the thermally labile (MET-3) and sulfate (MET-4a) conjugates of desalkyl delavirdine, 6’-hydroxy delavirdine (MET-7) and its glucuronide conjugate (MET-6), and the N-desisopropylpyridinepiperazine metabolite (MET-13, U-91976) were detected as minor components in mouse urine. In contrast, desalkyl delavirdine was the major (5–12% of the dose) drug-related material in rat urine, while MET-10 and MET-12 were very minor metabolites (27). Radioactivity in mouse feces was mostly composed of despiridyl delavirdine or intact delavirdine after administration of [14C-carboxamide] or [2-14C-pyr-idine]delavirdine mesylate, respectively. The differences in metabolite profiles obtained with the carboxamide and pyridine14C labels and the HPLC analysis of pre-dose feces fortified with [14C-carboxamide]delavirdine mesylate suggested that bacterial metabolism of delavirdine may account for the presence despiridyl delavirdine and MET-14 via degradation of 6’-hydroxy delavirdine.

The use of [13C]delavirdine mesylate proved to be indispensable for the identification of metabolites, especially to facilitate interpretation of mass spectra. Fragments containing all three 13C carbons are expected to give doublets 3 amu apart (A + 3), while fragments containing two or one 13C carbons would give A + 2 or A + 1 peaks, respectively, and those with no 13C atoms would yield singlets (see table 3). In addition, 13C NMR spectroscopy of the 13C3-enriched metabolites could readily be obtained—despite the minute quantities isolated—and this facilitated assignments owing to the presence of one-bond and two-bond carbon-carbon couplings.
fig. 7 illustrates the scheme for the metabolism of delavirdine in the mouse. The metabolism of delavirdine in the mouse involves four pathways: First, N-desalkylation to desalkyl delavirdine (MET-5, U-96183) is followed by conjugation with sulfate (MET-4a) or to MET-3. Second, hydroxylation of delavirdine at the pyridine ring C-6 position to 6'-hydroxy delavirdine (MET-7) and subsequent conjugation with glucuronic acid give 6'-O-glucuronide delavirdine (MET-6). Third, the pyridine ring in 6'-hydroxy delavirdine is cleaved to give despyridinyl delavirdine (MET-2, U-102466) and the pyridine ring-opened MET-14. Further conjugation of despyridinyl delavirdine gives MET-1. A fourth pathway involves amide bond cleavage with release of the N-isopropylpyridinepiperazine (MET-12, U-88703) and the indole carboxylic acid (MET-10, U-96364) metabolites and subsequent N-desalkylation to the N-desisopropylpyridinepiperazine metabolite (MET-13, U-91976) or conjugation of the indole carboxylic acid metabolite to MET-9. Amide bond cleavage represents a major pathway of biotransformation of delavirdine in the mouse, whereas in the rat it is a minor pathway (27).

Acknowledgments. The authors gratefully acknowledge L. R. Norris, R. J. Ouding, K. E. Rousch and T. L. VandeGiessen for technical assistance with animal dosimetry and sample collection. We also

| Proton | MET-10 | U-96364 | U-96364 + TEA | [13 C]3(Delavirdine)
|--------|--------|-------|---------|-----------------
| H-3    | 6.91 d | 7.12  | 6.94     | 6.86 d |
|        | (dd, 0.4H, 3J C2-C3 = 175 Hz) |        | (s, 1H) | (dd, 1H, 3J C2-C3 = 8 Hz) |
| H-4    | 7.49 (d, 1H, J 4,5  = 2.0 Hz) | 7.49 (d, 1H, J 4,5  = 2.1 Hz) | 7.40 (d, 1H, J 4,5  = 8.7 Hz) |
| H-6    | 7.40 (d, 1H, J 4,5  = 8.7 Hz) | 7.40 (d, 1H, J 4,5  = 2.0 Hz) | 7.40 (d, 1H, J 4,5  = 8.7 Hz) |
| H-7    | 7.40 (d, 1H, J 4,5  = 8.7 Hz) | 7.40 (d, 1H, J 4,5  = 8.7 Hz) | 7.40 (d, 1H, J 4,5  = 8.7 Hz) |
| H-4'   | 7.37 (d, 1H, J 4,5' = 8.0 Hz) | 7.27 (dd, 1H, J 4,5' = 8.0 Hz, J 5,5' = 5.5 Hz) |
| H-6'   | 7.64 (dd, 1H, J 6,5' = 1.2 Hz, J 6,5' = 5.5 Hz) |

<table>
<thead>
<tr>
<th>Carbon</th>
<th>MET-10</th>
<th>U-96364</th>
<th>U-96364 + TEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CO</td>
<td>169.8</td>
<td>164.5</td>
<td>168.4</td>
</tr>
<tr>
<td>C-2</td>
<td>—</td>
<td>6.91</td>
<td>130.5</td>
</tr>
<tr>
<td>C-3</td>
<td>105.5</td>
<td>6.91</td>
<td>105.3</td>
</tr>
<tr>
<td>C-3a</td>
<td>129.3</td>
<td>—</td>
<td>128.5</td>
</tr>
<tr>
<td>C-4</td>
<td>116.9</td>
<td>7.47</td>
<td>116.5</td>
</tr>
<tr>
<td>C-5</td>
<td>130.7</td>
<td>—</td>
<td>131.5</td>
</tr>
<tr>
<td>C-6</td>
<td>120.9</td>
<td>7.10</td>
<td>122.5</td>
</tr>
<tr>
<td>C-7</td>
<td>113.4</td>
<td>7.37</td>
<td>113.5</td>
</tr>
<tr>
<td>C-7a</td>
<td>135.7</td>
<td>—</td>
<td>135.2</td>
</tr>
<tr>
<td>CH3SO2N</td>
<td>2.88</td>
<td>2.88</td>
<td>37.8</td>
</tr>
</tbody>
</table>

References


Fig. 7. Metabolic pathway of delavirdine in mice.


